Elevated TRAF4 expression impaired LPS-induced autophagy in mesenchymal stem cells from ankylosing spondylitis patients

Jinteng Li1,3, Peng Wang1,3, Zhongyu Xie1,3, Rui Yang1, Yuxi Li1, Xiaohua Wu2, Hongjun Su2, Wen Deng2, Shan Wang2, Zhenhua Liu1, Shuizhong Cen1, Yi Ouyang1, Yanfeng Wu2 and Huiyong Shen1

Ankylosing spondylitis (AS) is a type of autoimmune disease that predominantly affects the spine and sacroiliac joints. However, the pathogenesis of AS remains unclear. Some evidence indicates that infection with bacteria, especially Gram-negative bacteria, may have an important role in the onset and progression of AS. Recently, many studies have demonstrated that mesenchymal stem cells (MSCs) dysfunction may contribute to the pathogenesis of many rheumatic diseases. We previously demonstrated that MSCs from AS patients exhibited markedly enhanced osteogenic differentiation capacity in vitro under non-inflammatory conditions. However, the properties of MSCs from AS patients in an inflammatory environment have never been explored. Lipopolysaccharide (LPS), a proinflammatory substance derived from the outer membrane of Gram-negative bacteria, can alter the status and function of MSCs. However, whether MSCs from AS patients exhibit abnormal responses to LPS stimulation has not been reported. Autophagy is a lysosome-mediated catabolic process that participates in many physiological and pathological processes. The link between autophagy and AS remains largely unknown. The level of autophagy in ASMSCs after LPS stimulation remains to be addressed. In this study, we demonstrated that although the basal level of autophagy did not differ between MSCs from healthy donors (HDMSCs) and ASMSCs, LPS-induced autophagy was weaker in ASMSCs than in HDMSCs. Specifically, increased TRAF4 expression in ASMSCs impaired LPS-induced autophagy, potentially by inhibiting the phosphorylation of Beclin-1. These data may provide further insight into ASMSC dysfunction and the precise mechanism underlying the pathogenesis of AS.

EXPERIMENTAL & MOLECULAR MEDICINE (2017) 49, e343; doi:10.1038/emm.2017.69; published online 9 June 2017

INTRODUCTION

Ankylosing spondylitis (AS) is a type of autoimmune disease that predominantly affects the spine and sacroiliac joints. The central pathological characteristics of AS are chronic inflammation and ectopic ossification. Several hypotheses for the mechanism underlying AS, including genetic susceptibility related to HLA-B27 or ERAP1 as well as environmental factors have been proposed. However, these hypotheses cannot fully explain the entire process of AS onset and progression. Recent evidence indicates that infection with bacteria, especially Gram-negative bacteria, may have an important role in the onset and progression of AS. However, the precise relationship between Gram-negative bacterial infection and AS must be explored further.

Mesenchymal stem cells (MSCs) are a cell type with strong potential for immunosuppression and tri-lineage differentiation. Recently, many studies have demonstrated that MSCs dysfunction may contribute to the pathogenesis of many rheumatic diseases. Our previous study demonstrated that MSCs from AS patients exhibited markedly enhanced osteogenic differentiation capacity in vitro under non-inflammatory conditions. However, the properties of MSCs from patients with inflammatory diseases such as AS in an inflammatory environment have never been explored.
Lipopolysaccharide (LPS), a proinflammatory substance derived from the outer membrane of Gram-negative bacteria, can alter the status and function of MSCs. However, whether MSCs from AS patients exhibit aberrant responses to LPS stimulation has never been reported.

Autophagy is a lysosome-mediated catabolic process that participates in many physiological and pathological processes. Recently, many studies have demonstrated that the level of autophagy, which can be affected by various factors, including LPS, reflects the status of MSCs. Moreover, several studies have demonstrated that abnormal autophagy contributes to the onset and progression of multiple autoimmune diseases, including inflammation in the gut of AS patients. However, the link between autophagy and AS remains largely unknown. The level of autophagy in ASMSCs after LPS stimulation remains to be addressed.

In this study, we first measured LPS-induced autophagy in both ASMSCs and healthy donors (HDMSCs), and then investigated the mechanisms of impaired LPS-induced autophagy in ASMSCs. These data may provide further insight into ASMSCs dysfunction and clues concerning the precise mechanism underlying the pathogenesis of AS.

**MATERIALS AND METHODS**

**Isolation and culture of MSCs**

This study was approved by the ethics committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. Written informed consent was obtained from all subjects included in the study (30 healthy donors and 30 patients with AS (diagnosed according to the modified New York criteria)). The characteristics of the subjects of this study are presented in Table 1. MSCs were isolated and cultured as previously described.15 Briefly, MSCs were isolated and purified from bone marrow using density gradient centrifugation at 12,000 r.p.m. for 30 min. The MSCs were then resuspended in MEM, USA) containing 10% fetal bovine serum (FBS, Hangzhou) and cultured as previously described.15 Brieﬂy, MSCs were isolated from bone marrow using density gradient centrifugation at 12,000 r.p.m. for 30 min. The protein extract was used for subsequent experiments.

**Flow cytometry**

MSCs were trypsinized for identification of several surface markers using human anti-CD29-PE, anti-CD44-V450A, anti-CD105-FITC, anti-CD45-FITC, anti-CD14-APC and anti-HLA-DR-PE antibodies (all purchased from BD Pharmingen, Franklin Lakes, NJ, USA). Flow cytometry was performed using a BD Influx cell sorter (BD Biosciences, Franklin Lakes, NJ, USA). The proliferation rate of MSCs was determined via the Cell Counting Kit-8 (CCK-8, Dojindo, Kumamoto, Japan) assay according to the manufacturer’s protocol. Medium lacking MSCs was used as a negative control.

**Quantitative real-time PCR**

High-throughput microfluidic fluorescence quantitative real-time PCR (qRT-PCR) was performed as previously described.15 Briefly, total RNA was extracted from MSCs using TRIzol (TaKaRa, Kusatsu, Japan) and then converted into cDNA using a PrimeScript™TM Reagent kit (Takara). The sample pre-mix and assay pre-mix were prepared and added to the respective inlets of a 48.48 Dynamic Array integrated fluidic circuit (IFC, Fluidigm, South San Francisco, CA, USA) that was primed and loaded in an IFC Controller MX (Fluidigm). qRT-PCR was performed in a BioMark HD System (Fluidigm), and the resulting data were analyzed using analysis software (Fluidigm). Real-time PCR was performed using a LightCycler 480 Real-Time PCR Detection System (Roche, Basel, Switzerland) using SYBR Green I Master Mix (Roche). The specific primers used for each gene are shown in Table 2. Data were first normalized by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression and then by the values in HDMSCs before LPS stimulation. The relative expression levels of each gene were determined using the 2−ΔΔCt method.

**Western blot**

Cells were washed three times with ice-cold PBS. Then, the cells were collected and lysed in RIPA buffer (Sigma) containing a cocktail of protease inhibitors (Roche) for 30 min on ice. Lysates were obtained via centrifugation at 12,000 r.p.m. at 4°C for 30 min. The protein concentration in the supernatant was determined using a BCA Protein Assay Kit (Sigma). Equal amounts of each sample diluted in 5× SDS loading buffer were subjected to SDS-polyacrylamide gel electrophoresis and were subsequently transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA). The membranes were blocked in 5% nonfat dry milk dissolved in TBST (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, and 0.05% Tween-20) at room temperature for 1 h and then incubated with primary antibodies against GAPDH
(1:1000, Cell Signaling Technology, Danvers, MA, USA), LC3B (1:1000, Sigma), P62 (1:1000, Cell Signaling Technology), TRAF4 (2.5 μg ml−1, R&D systems, Minneapolis, MN, USA), Beclin-1 (1:1000, Cell Signaling Technology) phospho-Beclin-1 (1:1000, Cell Signaling Technology) or specific K63-linked polyubiquitin (1:1000, Cell Signaling Technology) overnight at 4 °C. After washing three times in TBST, the membranes were incubated with the appropriate HRP-conjugated secondary antibodies (1:3000, Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at room temperature, followed by an additional three washes with TBST. The immunoreactive bands on the membranes were detected using chemiluminescent reagents (Millipore) according to the instructions provided by the manufacturer.

**Lentivirus construction and infection**

A lentivirus encoding short hairpin RNA (shRNA, GenePharma) targeting TRAF4 with the sequence 5′-GCACGATCAAGGATCGTC-3′ was added to the supernatant of the lentivirus vector containing green fluorescent protein-light chain 3B (GFP LC3B, GenePharma, Suzhou, China) at a multiplicity of infection of 50 with polybrene at a concentration of 5 μg ml−1. After 24 h, the culture medium was replaced according to the protocol provided by the manufacturer. At 72 h after transfection, when GFP-LC3B punctate fluorescence was efficiently expressed in the MSCs, GFP-LC3B was quantified, and for quantification, the number of GFP-LC3B dots per 100 cells was counted in 100 cells per sample using Image Pro Software (Roper Technologies, Sarasota, FL, USA).

**Table 2 Primers used for qRT-PCR**

| Gene      | Accession No. | Forward primer (5′–3′)         | Reverse primer (5′–3′) | Product size (bp) |
|-----------|---------------|--------------------------------|------------------------|-------------------|
| A20       | NM_006290     | TCTTACCAGCGGGTATTGTGAGGACG     | TGGTACGTGGTCATGTTTATA  | 124               |
| AP1       | NM_002228     | TCAAGTTGGCAGAAAAAGAAGG         | CGATGTCAGGCTTACTAAGGT  | 78                |
| ATG5      | NM_004849     | AAGATGTTGCCTGAGTATGTA          | CATCGGTCATGTTAACAAGCTA | 144               |
| ATG7      | NM_001144912 | ATGATCGCGCCATCGGAGGTC          | CACGGACGAAACAAACTCTAAC | 114               |
| ATG12     | NM_004707     | CTGCTGCAAGCAGACAAAGA           | CGTCGTGGCTCTACTCGCC    | 97                |
| ATG16L1   | NM_198890     | ATGCCGAGATGTCAGTCAGG           | GTCACACTTACATGCTGCT    | 138               |
| BCL2      | NM_000657     | GGTGGGCTACGTATGTTGTA           | CGGTACGTAGTACTGATCATCC | 89                |
| BECN1     | NM_003766     | GGTTCCTCGAGAGCACTACTC          | TCAGCTCGGCGTGGATGTCT   | 121               |
| GAPDH     | NM_001256799 | GAGAGCAATCGTACGTTA            | GGTTCGTTGACTAATCATGGA  | 197               |
| IKKa      | NM_001278     | GCTTTGGGGAAGCTGTTGTC           | TTTGGTATCTAGTCTGAGGGA  | 87                |
| IKKβ      | NM_001556     | GAAGTACTGCTGAAACAGTTGAGG       | GCAGAAGATGTGCTCATCAGAA | 147               |
| IKKγ      | NM_001193322 | TGCCCTGAGATGTAAGTTGGA          | ACAGAAATCGTGCTATCAGAA  | 119               |
| IRAK4     | NM_001145258 | CTCGACTCTCCAAACTGCAAGA         | GCAGAAGATGTGCTGAGGGA   | 101               |
| IRAKM     | NM_0007199    | CTGCAGATCTCCATCTATGGA          | AGTCCGAGATGCATCAGG     | 100               |
| IRF3      | NM_001197128 | AGAGGGTCGTCGATGTGCAAGG         | CGGTGTTGACCTGCTGTC     | 111               |
| IRF4      | NM_0002460    | GCTGATCGACCGACATGCACAG         | GCTCCGATGGTGATTCCCTG   | 138               |
| IRF5      | NM_001098630  | GGCTTCAAATGCTGCAACAGG         | GGGCCGATAGAAGAACTGCG   | 84                |
| IRF7      | NM_0004029    | CGTGGACGTCGACATCAGTGA          | AGTCTGATGACATGCTGCT    | 77                |
| IRF8      | NM_0002163    | ATGTAGTGACGCGGAGAAGTG          | TGTCGTGCTTCTGTGACT    | 84                |
| IRF9      | NM_0006084    | GGCACATCCTGTTAGTACCTTG         | CTGTCGCTCAGGTTCTAAGA   | 61                |
| MyD88     | NM_001172569 | GCAGATCCTCCAAACTGCAAGG         | TACCGGCAAAATTGCCAGGCCA | 191               |
| SOCS1     | NM_003745     | CAGGCACCCATCGACATCACCT         | GCTTGGTGTCGATCGGAGG    | 91                |
| RIP1      | NM_003804     | GGAAAGGTTGCTTGTGTTTTC          | TCCGCCATGGTCTGCAAGG    | 133               |
| TAK1      | NM_0032928    | CTCCTGCGCCATATTGTTGTA          | GTCACCTGCGGCTGACTTCTG  | 98                |
| TBK1      | NM_013254     | TGGGTGGAAGTACATCTCATGAGA       | GTCAGCGCAGAATTGCTGAGT  | 124               |
| TIRAP     | NM_148910     | GACCCCTGTGCCAAGTACC           | CGACGTCGACATGAGGAGG    | 133               |
| TRAF1     | NM_001190945  | TCTCTGGAAGATCACACATGGA         | GCAGGACACACCTTGAAGCC   | 117               |
| TRAF3     | NM_003300     | GCCTGCTGCAAGACAGACATGTT        | GCAGAGTCGGACATCAGTACT  | 133               |
| TRAF4     | NM_004295     | TATTTGCGCTGGTCCATGCG          | CAAAATCTCGCAATGAGGAGG  | 205               |
| TRAF6     | NM_145803     | ATGGCGCACTAGGTTGTCG           | TCCCTAGATGTCAGCTCATTG  | 198               |

Abbreviations: A20, tumor necrosis factor-alpha induced protein 3; AP1, activator protein 1; ATG5, autophagy-related 5; ATG7, autophagy-related 7; ATG12, autophagy-related 12; ATG16L1, autophagy-related 16 like 1; BECN1, beclin-1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IKKa, inhibitor of kappab kinase alpha; IKKβ, inhibitor of kappab kinase beta; IKKγ, inhibitor of kappab kinase epsilon; IKKε, inhibitor of kappab kinase gamma; IRAK4, interleukin-1 receptor-associated kinase 4; IRAKMK, interleukin-1 receptor-associated kinase M; IRF3, interferon regulatory factor 3; IRF4, interferon regulatory factor 4; IRF5, interferon regulatory factor 5; IRF7, interferon regulatory factor 7; IRF8, interferon regulatory factor 8; IRF9, interferon regulatory factor 9; MyD88, myeloid differentiation primary response 88; SOCS1, suppressor of cytokine signaling 1; RIP1, rieske iron–sulfur polypeptide 1; TANK, transforming growth factor-beta activated kinase 1; TBK1, TANK binding kinase 1; TIRAP, toll/interleukin-1 receptor-like protein domain-containing adaptor protein; TRAF1, tumor necrosis factor receptor-associated factor 1; TRAF3, tumor necrosis factor receptor-associated factor 3; TRAF4, tumor necrosis factor receptor-associated factor 4; TRAF6, tumor necrosis factor receptor-associated factor 6.
TTTG-3’ (Lv-TRAF4) was constructed. The negative control shRNA sequence was 5’-TTCTCCGAACGTTCAGTTTC-3’ (Lv-NC). Lentivirus (10^6 TU ml⁻¹) and polybrene (5 μg ml⁻¹, Sigma) were added to the medium and incubated with MSCs for 24 h at a multiplicity of infection of 50.

**Immunoprecipitation**

MSCs were quickly harvested and homogenized on ice in modified RIPA buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% (vol/vol) Triton X-100, 0.5% (wt/vol) sodium deoxycholate, 0.1% (wt/vol) SDS, 1 mM EDTA, 50 mM N-ethylmaleimide, 1 mM NaF, 1 mM Na3VO4, 1 mM PMSF and 1 μg ml⁻¹ each of aprotinin, leupeptin and pepstatin. The cell extracts (~200 μg of total protein) were incubated with an antibody against Beclin-1 (2.5 μg, Cell Signaling Technology) at 4 °C overnight. Then, protein-G agarose beads (40 μg, Beyotime Biotechnology, Shanghai, China) were added, and the mixture was incubated at 4 °C for 3 h. The agarose beads were collected, washed, and resuspended in 60 μl of sample buffer containing 50 mM Tris-HCl, pH 7.6, 2% (wt/vol) SDS, 10% (vol/vol) glycerol, 10 mM DTT and 0.2% bromophenol blue. Afterwards, the samples were boiled for 5 min and analyzed via western blot.

**Statistical analysis**

Experiments and subsequent analysis were performed separately by different authors in this study. All data are expressed as the means ± s.d. Statistical analysis was performed using SPSS 18.0 software (SPSS, Chicago, IL, USA). For statistical analysis, Student's t-test was performed to compare the means between two groups, or one-way analysis of variance followed by Bonferroni correction was performed for multiple comparisons among groups. P < 0.05 was considered statistically significant.

**RESULTS**

ASMSCs and HDMSCs showed similar morphologies, phenotypes and proliferative capacities

The morphologies of both HDMSCs and ASMSCs were plastic-adherent and spindle-shaped (Figure 1a). Regarding surface marker expression, both HDMSCs and ASMSCs were positive for CD29, CD44 and CD105 but negative for CD45, CD14 and HLA-DR; this expression pattern is characteristic of MSCs (Figure 1b). The growth curve of ASMSCs showed the same trend as that of HDMSCs (Figure 1c). In conclusion, there were no differences in morphology, phenotype or proliferative capacity between HDMSCs and ASMSCs.

LPS-induced autophagy is impaired in ASMSCs compared with that in HDMSCs

Because LC3-II accumulation in the cytoplasm is a specific hallmark of autophagy induction,33 we examined the effects of LPS on LC3-II accumulation in ASMSCs and HDMSCs. We first evaluated the expression of LC3-II in ASMSCs and HDMSCs after stimulation with 5 μg ml⁻¹ LPS for 0–24 h. Western blot analysis revealed that the endogenous LC3-II levels peaked after LPS stimulation for 8 h and declined thereafter in both ASMSCs and HDMSCs (Figure 2a). However, the level of LC3-II expression was higher in HDMSCs than in ASMSCs after LPS stimulation for 4, 8 or 16 h (Figure 2a). Next, we measured the expression of LC3-II in ASMSCs and HDMSCs after LPS stimulation for 8 h at different concentrations ranging from 1 to 20 μg ml⁻¹. LPS-induced autophagy in both ASMSCs and HDMSCs in a dose-dependent manner at concentrations of 1–5 μg ml⁻¹, but the autophagy upon stimulation with LPS was similar between concentrations ranging from 5 to 20 μg ml⁻¹ (Figure 2b). The expression of LC3-II was weaker in ASMSCs than in HDMSCs at LPS concentrations of 2–20 μg ml⁻¹, and the difference in autophagy between ASMSCs and HDMSCs peaked at 5 μg ml⁻¹ LPS (Figure 2b). The P62 protein, a specific autophagic substrate, is also used to monitor autophagy, and a lower level of P62 indicates stronger autophagy induction.34 In our study, the trend of P62 expression was opposite to that of LC3-II expression (Figures 2a and b). According to the above-mentioned results, subsequent experiments were conducted under conditions of LPS stimulation for 8 h at 5 μg ml⁻¹. Following LPS stimulation, fluorescence microscopy revealed a significant strong and punctate pattern of GFP-LC3 expression in HDMSCs but much weaker and more diffuse GFP-LC3 expression in ASMSCs (Figure 2c). In summary, these data demonstrated that LPS-induced autophagy was impaired in ASMSCs compared with that in HDMSCs.

**Gene and protein expression patterns of HDMSCs and ASMSCs after LPS stimulation**

To confirm the levels of autophagy induced by LPS stimulation and to explore the mechanism underlying the above-mentioned difference between ASMSCs and HDMSCs, we analyzed the gene expression of HDMSCs and ASMSCs after LPS stimulation using high-throughput qRT-PCR and confirmed the results via standard qRT-PCR. Our results demonstrated that the expression levels of autophagy-related genes including ATG5, ATG7, ATG12 and ATG16L1 were lower in ASMSCs after LPS stimulation (Figures 3a and b), confirming that LPS-induced autophagy was impaired in ASMSCs. In addition, we found that the mRNA expression of TRAF4, an important suppressor of signaling pathways,35,36 was much higher in ASMSCs than in HDMSCs both before and after LPS stimulation (Figures 3a and c). We then examined the protein levels of TRAF4 in ASMSCs and HDMSCs. Consistent with pattern of TRAF4 mRNA expression, TRAF4 protein expression was much higher in ASMSCs than in HDMSCs both before and after LPS stimulation (Figure 3d).

Silencing TRAF4 expression using Lv-TRAF4 abolished the discrepancy in LPS-induced autophagy between HDMSCs and ASMSCs

To explore the role of TRAF4 in the deficiency in LPS-induced autophagy in ASMSCs, we used Lv-TRAF4 to silence the expression of TRAF4 in ASMSCs and HDMSCs. As shown in Figure 4a, this lentivirus effectively transduced both HDMSCs and ASMSCs, and western blot confirmed that Lv-TRAF4 transduction markedly decreased the protein expression of TRAF4 to comparable levels between ASMSCs and HDMSCs.
after LPS stimulation (Figure 5a). Next, we assessed the level of Beclin-1 phosphorylation in ASMSCs and HDMSCs. As shown in Figure 5a, after LPS stimulation, the level of phosphorylated Beclin-1 was much lower in ASMSCs than in HDMSCs. In addition, Lv-TRAF4 transduction increased the levels of phosphorylated Beclin-1 in ASMSCs to that in HDMSCs after LPS stimulation (Figure 5b). Because phosphorylation of Beclin-1 is important for its autophagic activity, these results indicated that ASMSCs exhibit impaired LPS-induced autophagy due to their increased expression of TRAF4, which alters the phosphorylation of Beclin-1.

DISCUSSION

In this study, we demonstrated that even though there was no difference in the basal level of autophagy between HDMSCs and ASMSCs, LPS-induced autophagy was weaker in ASMSCs than in HDMSCs. Specifically, increased TRAF4 expression in ASMSCs impaired LPS-induced autophagy, potentially by inhibiting the phosphorylation of Beclin-1.

Recently, some authors have postulated that autoimmune diseases are stem cell-related disorders.12,41 Consistent with this hypothesis, our previous work demonstrated that ASMSCs have enhanced osteogenic differentiation potential in the absence inflammatory stimulation, which may be a mechanism of pathological osteogenesis in AS.15 These data indicated that ASMSCs were abnormal. However, the status and functions of MSCs are plastic in response to multiple factors, such as inflammation and hypoxia.12,43 Considering that AS is a type of inflammatory disease, studying the abnormalities in ASMSCs in an inflammatory microenvironment will have clinical and scientific research value.

Infection with bacteria, especially Gram-negative bacteria, is thought to actively participate in the pathogenesis of AS.7–9 LPS is an important proinflammatory substance derived from the outer membrane of Gram-negative bacteria.16 It has been reported that AS patients had significantly elevated serum levels of antibodies against LPS compared to those of healthy controls and that LPS antibody levels strongly correlated with the levels of the acute-phase reactant C-reactive protein.44 Therefore, LPS should be considered an important component of the inflammatory microenvironment in AS. In addition, other studies have demonstrated that stimulation with LPS modulates the status or the function of MSCs.17,18 Therefore, we explored the status and function of ASMSCs under conditions of LPS stimulation and assessed whether ASMSCs exhibit any abnormalities in response to LPS stimulation compared with HDMSCs.

Autophagy is a lysosome-mediated catabolic process that maintains cellular homeostasis by degrading and recycling cytoplasmic components or organelles.45 The biological implications of insufficient or excessive autophagic activity are a rapidly growing area of study.46 Previous hypotheses that autophagy is strictly a catabolic recycling process are now being expanded. Although the association between autophagy and rheumatic diseases has been widely studied in past years, the relationship between autophagy and AS remains largely

![Figure 1](image-url)  

**Figure 1** ASMSCs and HDMSCs showed comparable morphologies, proliferative activities and phenotypes. (a) The morphologies of MSCs were observed via microscopy (×40, scale bar = 50 μm); ASMSCs (n = 30) and HDMSCs (n = 30) shared the same morphologies. (b) Both ASMSCs (n = 30) and HDMSCs (n = 30) were positive for CD29, CD44 and CD105 but negative for CD14, CD45 and HLA-DR; this surface marker expression pattern is characteristic of MSCs. (c) The growth curve of ASMSCs (n = 30) was similar to that of HDMSCs (n = 30) cultured in medium from 0 to 11 days. Values in c are presented as the means ± s.d. ASMSCs, ankylosing spondylitis mesenchymal stem cells; HDMSCs, healthy donors mesenchymal stem cells; MSCs, mesenchymal stem cells.
unknown. The two central features in AS that require explanation are inflammation and new bone formation.\(^1\) However, the pathogenesis of these two features remains largely unknown. The potential role of autophagy in the pathogenesis of these two features requires further exploration. As in peripheral blood mononuclear cells (PBMCs), defective autophagy can contribute to increased inflammation through a failure to regulate the release of several proinflammatory cytokines, including IL-1\(\beta\), IL-17 and IL-23.\(^47-49\) Autophagy can regulate multiple functions of MSCs.\(^50-52\) One of the characteristics of MSCs is their immunoregulation ability, and autophagy has an important role in modulating this ability.\(^52\) Defects of MSCs in immune regulation may contribute to the pathogenesis of inflammation.\(^53,54\) Our data demonstrated that LPS-induced autophagic activity was much weaker in ASMSCs than in HDMSCs. Thus, the impairment of LPS-induced autophagy in ASMSCs may suppress their immunoregulation ability in an inflammatory microenvironment and, in turn, contribute to the pathogenesis of inflammation in AS. As mentioned above, another central feature of AS is new bone formation, and there are few studies about the pathogenesis of pathological osteogenesis in AS. MSCs are precursor cells of osteoblasts,\(^55\) and we have previously demonstrated that ASMSCs have enhanced osteogenic differentiation potential in the absence of inflammatory stimulation, which may be a mechanism of pathological osteogenesis in AS. Autophagy also modulates the differentiative capacity of MSCs.\(^51,56\) Thus, the impairment of LPS-induced autophagy in ASMSCs may influence their osteogenesis in an inflammatory microenvironment and, in turn, contribute to the pathogenesis of pathological osteogenesis in AS. Conversely, other studies have shown that the level of autophagic activity is elevated in the subclinically inflamed gut of AS patients,\(^27\) indicating the opposite association between autophagy and AS. Similarly,
both insufficient and excessive autophagy have been reported in rheumatoid arthritis (RA); for example, one study found that reduced autophagy in T cells resulted in immune system abnormalities,\(^5^7\) whereas another study found that enhanced autophagy contributed to hyperplasia in synovium from RA patients.\(^2^5\) Therefore, autophagy could have a dual role in the pathogenesis of RA, as both enhanced and reduced autophagy contribute to malfunctions observed in RA. Considering the complex role of autophagy in regulating different physiological and pathological processes, this ‘discrepancy’ in the function of autophagy in rheumatic diseases including AS is very likely caused by differences in cell types or tissues examined between studies. To identify the role of autophagy in AS, the level of autophagic activity in different types of cells and tissues related to AS should be studied. Elucidating the precise role of the impairment of LPS-induced autophagy in AS will be a focus of our future studies.

In addition, our study raises an intriguing question. Decreased protein levels of P62 are often used as a typical marker of autophagy.\(^5^8\) However, some studies have demonstrated that LPS-induced autophagy is P62-dependent; upon LPS stimulation, the protein level of P62 increases, resulting in induction of autophagy.\(^5^9,^6^0\) However, in our study, LPS-induced autophagy in MSCs was also accompanied by degradation of P62, which appears to contradict this previous observation. Indeed, the expression pattern of P62 during LPS-induced autophagy appears to be controversial. Some studies have demonstrated that the expression of P62 is increased after LPS stimulation following the typical expression

**Figure 3** Gene and protein expression patterns of HDMSCs and ASMSCs after LPS stimulation. (a) High-throughput qRT-PCR was performed to determine the gene expression of important molecules related to the LPS-induced autophagy process in ASMSCs (n=30) and HDMSCs (n=30). H1-H3 and A1-A3 represent three samples randomly selected from the 30 healthy donors and the 30 AS patients, respectively. The heat maps show the $\Delta\Delta$CT values. Each column represents one sample, and each row represents one gene. The results indicated that ASMSCs (A) had lower expression of ATG5, ATG7, ATG12 and ATG16L1 than HDMSCs (H) after LPS stimulation but higher expression of TRAF4 both before and after LPS stimulation. (b, c) Standard qRT-PCR was performed to confirm the results of high-throughput qRT-PCR. The standard qRT-PCR results were consistent with those of high-throughput qRT-PCR (n=30). (d) The protein level of TRAF4 was evaluated in ASMSCs (n=30) and HDMSCs (n=30) before and after LPS stimulation. The TRAF4 protein expression levels were consistent with the TRAF4 mRNA expression levels: TRAF4 protein expression was much higher in ASMSCs than in HDMSCs both before and after the LPS stimulation. The figures in d are typical examples of MSCs from one healthy donor and one AS subject. The values in b-d are presented as the means±s.d.; *P<0.05. The high-throughput and standard qRT-PCR data were first normalized to GAPDH expression and then normalized to the values of H1 before LPS stimulation, and the relative expression levels of each gene were analyzed using the $2^{-\Delta\Delta\text{CT}}$ method. AS, ankylosing spondylitis; ASMSCs, ankylosing spondylitis mesenchymal stem cells; HDMSCs, healthy donors mesenchymal stem cells; LPS, lipopolysaccharide; MSCs, mesenchymal stem cells; qRT-PCR, quantitative real-time PCR.
However, we have identified several differences among these studies. First, the types of cells used in these studies are very different. Most studies that demonstrated that P62 is increased during LPS-induced autophagy used macrophages in their experiments, whereas studies demonstrating that P62 is decreased, consistent with our results, used epithelial or endothelial cells. Second, although the LPS stimulation times in these studies were similar, the concentrations of LPS differed. The concentration of LPS used in the studies showing an increase in P62 ranged from 0.1 to 1 μg ml⁻¹, whereas the concentrations in the studies in which P62 decreased were often >1 μg ml⁻¹. Thus, differences in cell type and LPS concentration may be responsible for the discrepancies in P62 levels.

To elucidate the mechanism underlying this abnormal LPS-induced autophagy, we measured the expression of several critical molecules related to this process. Our results demonstrated that TRAF4 expression was elevated in ASMSCs. After silencing TRAF4 using a lentivirus, the difference in LPS-induced autophagy between ASMSCs and HDMSCs was abolished. This result suggested that elevated expression of TRAF4 was the main cause of the abnormality in LPS-induced autophagy in ASMSCs. TRAF4 belongs to the TRAF family, which consists of signal transducers for multiple signaling pathways. In contrast to other TRAF members, TRAF4 acts as a suppressor of many signaling pathways and thus prevents excessive activation of these pathways. Similarly, our results indicated that TRAF4 negatively regulated LPS-induced autophagy. Therefore, TRAF4 acts as a suppressor of LPS-induced autophagy and thus prevents overreactions to LPS stimulation under normal conditions. However, upon pathological upregulation of TRAF4 in ASMSCs, TRAF4 impairs LPS-induced autophagy in ASMSCs compared with HDMSCs. In addition, we observed an interesting phenomenon: TRAF4 was also upregulated in ASMSCs under basal conditions, but there was no difference in the basal status of autophagy between HDMSCs and ASMSCs. It is possible that the basal status of autophagy even in HDMSCs is very weak that the elevated expression of TRAF4 in ASMSCs can hardly further suppress the basal level of autophagy. Thus, the basal status of autophagy is comparable between ASMSCs and

---

**Figure 4** Inhibiting TRAF4 expression using Lv-TRAF4 abolished the difference in LPS-induced autophagy between HDMSCs and ASMSCs. (a) GFP-positive cells were observed under a confocal microscope (×50, scale bar=200 μm), and the transduction efficiencies were equivalent between HDMSCs (n=30) and ASMSCs (n=30). (b) The expression levels of TRAF4, LC3-II and P62 in ASMSCs (n=30) and HDMSCs (n=30) were determined. Lv-TRAF4 effectively decreased the expression of TRAF4 in both ASMSCs and HDMSCs compared with that in the control and Lv-NC treatments before and after LPS stimulation. Lv-TRAF4 transduction led to increased LC3-II expression but decreased P62 expression in both ASMSCs and HDMSCs after LPS stimulation. In addition, silencing TRAF4 abolished the differences in LC3-II and P62 expression between HDMSCs and ASMSCs after LPS stimulation. The figures in b are typical examples of MSCs from one healthy donor and one AS subject. (b) are presented as the means±s.d.; *P<0.05. The control group consisted of MSCs not transduced with lentivirus. The Lv-NC group consisted of MSCs transduced with lentivirus encoding a negative control shRNA sequence. The Lv-TRAF4 group consisted of MSCs transduced with lentivirus encoding shRNA targeting TRAF4. AS, ankylosing spondylitis; ASMSCs, ankylosing spondylitis mesenchymal stem cells; HDMSCs, healthy donors mesenchymal stem cells; LPS, lipopolysaccharide; MSCs, mesenchymal stem cells.
HDMSCs. However, upon LPS stimulation, autophagy is strongly induced in HDMSCs, but this process is suppressed by upregulated TRAF4 in ASMSCs, in turn causing impairment in autophagic activity in ASMSCs in an environment of LPS stimulation.

To our knowledge, few studies have explored the relationship between TRAF4 and autophagy. Previous studies have demonstrated that other TRAFs modulate the function of Beclin-1. Beclin-1 is the key molecule for induction of autophagy that initiates the formation of autophagosomes by helping localize other autophagy-related proteins to the pre-autophagosomal membrane. Thus, we examined whether Beclin-1 is involved in the impairment in LPS-induced autophagy in ASMSCs. In this study, we evaluated the expression and K63-linked ubiquitination and phosphorylation of Beclin-1 after LPS stimulation in ASMSCs and HDMSCs. We did not observe any difference in the expression or K63-linked ubiquitination of Beclin-1 between ASMSCs and HDMSCs. However, after LPS stimulation, the induction of Beclin-1 phosphorylation was much weaker in ASMSCs than in HDMSCs. Considering that Beclin-1 acts as an initiator of autophagy, K63-linked ubiquitination and phosphorylation of Beclin-1 are essential for its induction of autophagic activity, and decreasing either K63-linked ubiquitination or phosphorylation of Beclin-1 leads to impairment of autophagy induction. In our study, LPS-induced K63-linked ubiquitination of Beclin-1 was comparable between ASMSCs and HDMSCs, and this finding indicated that this ubiquitination process was not involved in the reduction in LPS-induced autophagy in ASMSCs. However, LPS-induced phosphorylation of Beclin-1 was much weaker in ASMSCs than in HDMSCs. Moreover, silencing TRAF4 in ASMSCs significantly enhanced the level of phosphorylated Beclin-1 in ASMSCs after LPS stimulation to a level comparable to that in HDMSCs. This observation was consistent with the above results that silencing TRAF4 in ASMSCs increased LPS-induced autophagic activity to the same level as that measured in HDMSCs. Therefore, our results indicated that phosphorylation of Beclin-1 might be involved in the impairment in LPS-induced autophagy in ASMSCs caused by increased TRAF4 expression.

In conclusion, our results have confirmed that LPS-induced autophagy was weaker in ASMSCs than in HDMSCs because of elevated expression of TRAF4, potentially by altering the phosphorylation of Beclin-1. These findings imply a possible...
role of MSC abnormalities in AS. However, there are many limitations to the present study. First, the mechanism by which TRAF4 suppresses LPS-induced phosphorylation of Beclin-1 remains unclear. Second, we have confirmed only that LPS-induced autophagy was reduced in ASMSCs, but the association of this reduction with ASMSC dysfunction in an inflammatory environment has yet to be concretely established. Our future research aims to address these limitations.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
This study was financially supported by the National Natural Science Foundation of China (81672128, 81672097) and the Science and Technology Project of Guangdong Province (2015B02228001, 2015B090903059).

1 Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369: 1379–1390.
2 Caffrey MF, James DC. Human lymphocyte antigen association in ankylosing spondylitis. Nature 1973; 242: 121.
3 Davidson SI, Wu X, Liu Y, Wei M, Danoy PA, Thomas G. ERAP1, but not IL23R, with ankylosing spondylitis in a Han Chinese population. Arthritis Rheum 2009; 60: 3263–3268.
4 Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 2011; 43: 761–767.
5 Brown MA, Kennedy LG, Macgregor AJ, Darke C, Duncan E, Shafford JL et al. Susceptibility to ankylosing spondylitis in twins the role of genes, HLA, and the environment. Arthritis Rheum 1997; 40: 1823–1828.
6 Calin A, Elwood J. Relative role of genetic and environmental factors in disease expression: sib pair analysis in ankylosing spondylitis. Arthritis Rheum 1989; 32: 77–81.
7 Martinez A, Pacheco-Tena C, Vázquez-Mellado J, Burgos-Vargas R. Relationship between disease activity and infection in patients with spondyloarthopathies. Ann Rheum Dis 2004; 63: 1338–1340.
8 Zochling J, Bohl-Bühler MH, Baraliakos X, Feldtkeller E, Braun J. The high inflammatory environment has yet to be concretely established.
9 Zalckvar E, Berissi H, Mizrahy L, Idelchuk Y, Koren I, Eisenstein M et al. Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 in the gut of patients with ankylosing spondylitis and subclinical gut inflammation. Ann Rheum Dis 2014; 73: 1566–1574.
10 van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361–366.
11 Inokuchi-Shimizu S, Park EJ, Roh YS, Yang L, Zhang B, Song JY et al. TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis. J Clin Invest 2014; 124: 3566–3578.
12 Shi CS, Kehrl JH. MyD88 and Trif target Beclin 1 to trigger autophagy in macrophages. J Biol Chem 2008; 283: 33175–33182.
13 Hosokawa N, Sasaki T, Iemura S, Natsume T, Hara T, Mizushima N. Atg101, a novel mammalian autophagy protein interacting with Atg13. Autophagy 2009; 5: 973–979.
14 Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 2010; 140: 313–326.
15 Tanida I, Ueno T, Komaromi I. LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol 2004; 36: 2503–2518.
16 Komatsu M, Ichimura Y. Physiological significance of selective degradation of p62 by autophagy. FEBS Lett 2010; 584: 134–139.
17 Takeshita F, Ishii KJ, Kobiyama K, Kojima Y, Coban C, Sasaki S et al. TRAF4 acts as a silencer in TLR-mediated signaling through the association with TRAF6 and TRIF. Eur J Immunol 2005; 35: 2477–2485.
18 Marinis JM, Hutti JE, Homer CR, Cobb BA, McDonald C et al. I kappa B kinase alpha phosphorylation of TRAF4 downregulates innate immune signaling. Mol Cell Biol 2012; 32: 2479–2489.
19 Stu CS, Kehrl JH. TRAF6 and A20 regulate lysine 63-linked ubiquitination of Beclin-1 to control TLR4-induced autophagy. Sci Signal 2010; 3: ra42.
20 Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ 2011; 18: 571–580.
21 Zalckvar E, Berissi H, Mizrahy L, Igelchuk Y, Koren I, Eisenstein M et al. DAP kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl-XL and induction of autophagy. EMBO Rep 2009; 10: 285–292.
22 Russell RC, Tian Y, Yuan HX, Park HW, Chang YY, Kim J et al. ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase. Nat Cell Biol 2013; 15: 741–750.
23 Ikehara S, Kawamura M, Takao F, Inaba M, Yasmiruzu R, Than S et al. Organ-specific and systemic autoimmune diseases originate from defects in hematopoietic stem cells. Proc Natl Acad Sci USA 1990; 87: 8341–8344.
24 Liu Y, Han ZP, Zhang SS, Jing YY, Bu XX, Wang CY et al. Effects of inflammatory factors on mesenchymal stem cells and their role in the

Experimental & Molecular Medicine
promotion of tumor angiogenesis in colon cancer. J Biol Chem 2011; 286: 25007–25015.

43 Grayson WL, Zhao F, Bunnell B, Ma T. Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. Biochem Biophys Res Commun 2007; 358: 948–953.

44 Ahmed K, Wilson C, Tiwana H, Binder A, Ebringer A. Antibodies to Klebsiella pneumoniae lipopolysaccharide in patients with ankylosing spondylitis. Br J Rheumatol 1998; 37: 1330–1333.

45 Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000; 290: 1717–1721.

46 Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132: 27–42.

47 Shi CS, Shenderov K, Huang NN, Binder JA, Abu-Asab M, Fitzgerald KA et al. Activation of autophagy by inflammatory signals limits IL-1 beta production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol 2012; 13: 255–263.

48 Peral de Castro C, Jones SA, Ni Cheallaigh C, Hearnden CA, Williams L, Winter J et al. Autophagy regulates IL-23 secretion and innate T cell responses through effects on IL-1 secretion. J Immunol 2012; 189: 4144–4155.

49 Brereton CF, Sutton CE, Ross PJ, Iwakura Y, Pizza M, Rappuoli R et al. Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production. J Immunol 2011; 186: 5896–5906.

50 Hou J, Han ZP, Jing YY, Yang X, Zhang SS, Sun K et al. Autophagy prevents irradiation injury and maintains stemness through decreasing ROS generation in mesenchymal stem cells. Cell Death Dis 2013; 4: e844.

51 Oliver L, Hue E, Priault M, Vallette FM. Basal autophagy decreased during the differentiation of human adult mesenchymal stem cells. Stem Cells Dev 2012; 21: 2779–2788.

52 Dong SP, Xu HB, Xu CF, Cai W, Li Q, Cheng YJ et al. Autophagy regulates the therapeutic potential of mesenchymal stem cells in experimental autoimmune encephalomyelitis. Autophagy 2014; 10: 1301–1315.

53 Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther 2012; 20: 14–20.

54 Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 2013; 13: 392–402.

55 Heino TJ, Hentunen TA. Differentiation of osteoblasts and osteocytes from mesenchymal stem cells. Curr Stem Cell Res Ther 2008; 3: 131–145.

56 Tao J, Wang HN, Zhai Y, Park H, Wang J, Ji F et al. Downregulation of Nrf2 promotes autophagy-dependent osteoblastic differentiation of adipose-derived mesenchymal stem cells. Exp Cell Res 2016; 349: 221–229.

57 Yang Z, Fujii H, Mohan SW, Goronzy JJ, Weyand CM. Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells. J Exp Med 2013; 210: 2119–2134.

58 Pankiv S, Clausen TH, Lamark T, Brech A, Brunu JA, Outzen H et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 2007; 282: 24131–24145.

59 Fujita KI, Srinivasula SM. TLR4-mediated autophagy in macrophages is a p62-dependent type of selective autophagy of aggresome-like induced structures (ALIS). Autophagy 2011; 7: 552–554.

60 Chen S, Yuan JX, Yao SQ, Jin YL, Chen G, Tian W et al. Lipopolysaccharides may aggravate apoptosis through accumulation of autophagosomes in alveolar macrophages of human silicosis. Autophagy 2015; 11: 2346–2357.

61 Li SY, Guo L, Qian P, Zhao YF, Liu A, Ji FY et al. Lipopolysaccharide induces autophagic cell death through the PERK-Dependent branch of the unfolded protein response in human alveolar epithelial A549 cells. Cell Physiol Biochem 2015; 36: 2403–2417.

62 Inoue JI, Ishida T, Tsukamoto N, Kobayashi N, Naito A, Azuma S et al. Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp Cell Res 2000; 254: 14–24.

63 Xia PY, Wang S, Du Y, Zhao ZN, Shi L, Sun L et al. WASH inhibits autophagy through suppression of Beclin 1 ubiquitination. EMBO J 2013; 32: 2685–2696.

64 Fujikawa N, Usui T, Ohama T, Sato K. Regulation of Beclin 1 protein phosphorylation and autophagy by protein phosphatase 2A (PP2A) and death-associated protein kinase 3 (DAPK3). J Biol Chem 2016; 291: 10858–10866.